title: Transcatheter arterial embolic therapies for hepatocellular carcinoma: a literature review.
abstract: Palliative therapies for hepatocellular carcinoma (HCC) include transcatheter arterial embolic therapies, radiation therapy and systemic chemotherapies such as sorafenib. Conventional transcatheter arterial chemoembolization (cTACE) is the golden standard for the treatment of intermediate-stage HCC, and involves the administration of chemotherapuetic drugs, with or without lipiodol, by means of a catheter directly to the feeding artery of the targeted tumor followed by administration of embolic agents, while the concept of drug-eluting bead TACE (DEB-TACE) builds on the rationale for cTACE. DEB-TACE has been demonstrated to substantially improve the pharmacokinetic profile of TACE, providing levels of consistency and repeatability in patients that are not available with cTACE. On the other hand, the technique of radioembolization therapy for HCC involves the delivery of high-dose radiation via the hepatic artery. In the present review, we summarize the current status of these transcatheter arterial embolic therapies in HCC.
authors.affiliation: Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan h-nishikawa@osaka-med.jrc.or.jp.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Nishikawa
authors.affiliation: Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan.
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Kita
authors.affiliation: Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan.
authors.forename: Toru
authors.initials: T
authors.lastname: Kimura
authors.affiliation: Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan.
authors.forename: Yukio
authors.initials: Y
authors.lastname: Osaki
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D015251:Epirubicin / Q000008:administration & dosage / Q000627:therapeutic use; D004998:Ethiodized Oil / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008099:Liver / Q000098:blood supply / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D015251:Epirubicin; C406530:miriplatin; D004998:Ethiodized Oil; D004317:Doxorubicin; D002945:Cisplatin
keywords: Hepatocellular carcinoma; combination therapy; radioembolization; review; transcatheter arterial chemoembolization